SAR441340
Phase 2
SanofiSAR441340 is one of 36 therapeutic programs targeting Systemic Sclerosis. It is currently in Phase 2.
1
Indications
0
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
165 competitors in Systemic Sclerosis
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Actemra
RochePhase 3
Medrol
PfizerPhase 3
Opsumit
Johnson & JohnsonPhase 3
Rinvoq
AbbViePhase 3
Cysteine Hydrochloride
NovartisPhase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Ofev
Boehringer IngelheimPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Esbriet
LLegacy Health System
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for SAR441340. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company